ArticleEClinicalMedicine2026
Mapping the readiness landscape for prostate cancer screening in Europe: analysis of health system capacity across the PRAISE-U pilots.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06424275 (Prostate Cancer Awareness and Initiative for Screening in the European Union), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prostate Cancer Awareness and Initiative for Screening in the European Union
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) remains the most frequently diagnosed cancer and a leading cause of cancer mortality among European men. To support the European Commission's call for organised, risk-stratified PCa screening, the PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union) pilots tested a designated pathway integrating prostate-specific antigen (PSA) testing, risk stratification and magnetic resonance imaging (MRI)-guided biopsy decisions. Methods: A formative readiness and capacity assessment was conducted across five PRAISE-U pilots in Lithuania, Lower Silesia (Poland), Manresa and Galicia (Spain), and Ireland. Data were triangulated from (1) desk reviews of legislation, screening policies, and relevant documentation; (2) facility-level assessments; and (3) multi-level stakeholder consultations collected between November 2023 and mid 2024. Finally 47 indicators across 11 domains were developed. Indicators were scored on a standardised 0-2 scale, aggregated at the domain level, and visualised using radar plots. The PRAISE-U was registered with ClinicalTrials.gov, number NCT06424275. Findings: Substantial heterogeneity was observed across sites. Clinical domains (PSA testing availability, diagnostics, treatment, infection control, multidisciplinary teams and active surveillance protocols) scored high across all pilots. However, the programmatic "front-end" elements (awareness activities, eligibility identification, counselling Standard Operating Protocol) and "back-end" elements (systematic tracking of screen-positives, Quality Assurance and registry linkage) were noted weak and heterogeneous across sites. Lithuania demonstrated the highest overall readiness, while other pilots faced challenges in population identification, data governance, and structured follow-up of screen-positive individuals. Interpretation: While European pilot sites show robust clinical capacity for PCa care, substantial gaps remain in the organisational, data, and quality-assurance components, that warranted an effective population-based, risk-stratified PCa screening. Funding: This project has received funding from the EU4Health program under grant agreement 101101217, co-funded by the European Union.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.